Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty

Heart

Volumn 85, Issue 4, 2001, Pages 444-450

  Akkerhuis, K M ^a   Van den Brand, M J B M ^a   Van der Zwaan, C ^a   Peels, H O J ^b   Suryapranata, H ^c   Van der Wieken, L R ^d   Stibbe, J ^a   Hoffmann, J ^e   Baardman, T ^e   Deckers, J W ^f   Simoons, M L ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c HOSPITAL DE WEEZENLANDEN   (Netherlands)

^d ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f CARDIALYSIS   (Netherlands)

Author keywords

Angioplasty; Glycoprotein IIb IIIa blockers; Lefradafiban; Platelet aggregation inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST; FRADAFIBAN; HEPARIN; LEFRADAFIBAN; PLACEBO;

ADULT; AGED; ANGIOPLASTY; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NETHERLANDS; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR OCCUPANCY; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0034763284     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.85.4.444     Document Type: Article

References (30)

1. The pathogenesis of coronary artery disease and the acute coronary syndromes
2. Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty
3. Predicting the risk of abrupt vessel closure after angioplasty in an individual patient
4. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine
5. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
6. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
7. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
8. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
9. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II
10. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
11. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
12. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
13. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
14. Profound and sustained inhibition of platelet aggregation by fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug lefradafiban in men
15. Thrombolysis in myocardial infarction (TIMI) trial. Phase I: A comparison between intravenous plasminogen activator and intravenous streptokinase
16. Thrombolysis in myocardial infarction (TIMI) trial - Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
17. A bleeding risk index for estimating the probability of major bleeding in hospitalized patients starting anticoagulant therapy
18. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: Results of a multicenter, placebo-controlled, randomized trial
19. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: Results of the TIMI 12 trial
20. Monitoring platelet GP IIb/IIIa antagonist therapy
21. Rapid platelet-function assay: An automated and quantitative cartridge-based method
22. Ticlopidine-associated aplastic anemia. A case report and review of literature
23. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomized trial
24. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia
25. 3) inhibitors
26. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels
27. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban